Senseonics Holdings and Sequel MedTech announced that the first commercial patients received the Eversense 365 implantable continuous glucose monitor paired with Sequel’s twiist automated insulin delivery system on January 8 2026. The activation marks the first time a one‑year CGM has been integrated with an AID platform, a milestone that could accelerate the adoption of fully automated diabetes management for type 1 patients.
The integration combines Senseonics’ durable, implantable sensor with Sequel’s iiSure insulin‑delivery technology and the Tidepool Loop algorithm that drives real‑time dosing. The Eversense 365’s year‑long wear time and reduced calibration requirements give it a distinct advantage over traditional CGMs, while the twiist system’s precise insulin measurement supports safer, more accurate automated therapy.
Financially, Senseonics reported a net loss of $15.5 million and revenue of $22.5 million in Q4 2024, with full‑year 2024 revenue at $22.5 million and a 2025 revenue outlook of $34–$38 million. The company’s transition to a direct U.S. commercial model beginning January 1 2026 is expected to improve margin recognition and accelerate revenue growth.
CEO Tim Goodnow said the partnership “marks a significant step forward in transforming diabetes care,” while Sequel CEO Alan Lotvin highlighted the value of personalized, choice‑driven therapy. Both executives emphasized that the collaboration expands Senseonics’ addressable market and creates a new recurring revenue stream as patients move to the AID system.
The news was well received by investors, with analysts noting the launch’s potential to broaden Senseonics’ product portfolio and improve profitability. Market participants also acknowledged ongoing cash burn and the need for continued cost discipline, but viewed the integration as a positive catalyst for future growth.
Strategically, the launch positions Senseonics to compete more directly with established CGM and pump makers such as Medtronic, Tandem, and Insulet. By offering a durable, one‑year sensor integrated with an AID platform, Senseonics can differentiate itself in a rapidly expanding automated insulin delivery market and potentially capture a larger share of the growing diabetes technology ecosystem.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.